lobbying_activities: 2421824

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2421824	df03fd0f-2edd-4fb2-b4fc-9941d9bfbe51	Q1	JOHNSON MATTHEY INC.	401104441	JOHNSON MATTHEY INC.	2020	first_quarter	PHA	H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers.	HOUSE OF REPRESENTATIVES,SENATE		10000	0	0	2020-04-07T14:47:47.110000-04:00